Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Expenses: 2020-2025

Historic Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $67.6 million.

  • Xeris Biopharma Holdings' Operating Expenses rose 0.73% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.3 million, marking a year-over-year increase of 10.24%. This contributed to the annual value of $236.7 million for FY2024, which is 13.85% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Operating Expenses stood at $67.6 million, which was up 0.88% from $67.1 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Operating Expenses' 5-year high stood at $69.7 million during Q4 2021, with a 5-year trough of $24.9 million in Q1 2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median Operating Expenses value was $56.3 million (recorded in 2024), while the average stood at $58.4 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Operating Expenses soared by 114.88% in 2021 and then crashed by 30.68% in 2022.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Operating Expenses stood at $69.7 million in 2021, then tumbled by 30.68% to $48.3 million in 2022, then climbed by 12.25% to $54.2 million in 2023, then increased by 7.72% to $58.4 million in 2024, then rose by 0.73% to $67.6 million in 2025.
  • Its Operating Expenses was $67.6 million in Q3 2025, compared to $67.1 million in Q2 2025 and $63.2 million in Q1 2025.